NCT06867952View on ClinicalTrials.gov

A Pilot Study of Vitamin K2 (Menaquinone-7, Soloways ™) in Patients With Osteopenia/Osteoporosis Carrying a VDR Gene Variant

NARecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

May 3, 2024

Primary Completion Date

February 28, 2026

Study Completion Date

March 3, 2026

Conditions
OsteoporosisOsteopenia
Interventions
DIETARY_SUPPLEMENT

Vitamin K2 plus vitamin D3

Intervention: Vitamin K2 (menaquinone-7), 100-200 µg/day plus vitamin D3 (800- 1000 IU/day) for 6-9 months.

DIETARY_SUPPLEMENT

Vitamin K2 plus vitamin D3

Intervention: Vitamin K2 (menaquinone-7), 100-200 µg/day plus vitamin D3 (800- 1000 IU/day) for 6-9 months.

Trial Locations (1)

630090

RECRUITING

Center For New Medical Technologies, Novosibirsk

All Listed Sponsors
collaborator

Center for New Medical Technologies, Novosibirsk, Russia

OTHER

lead

S.LAB (SOLOWAYS)

OTHER